Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label long-term safety and efficacy study of CM310 in adults with moderate-to-severe atopic dermatitis
CTR20233449Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Dec 2023; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20233449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233449.